A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine.
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- Sponsors CoLucid Pharmaceuticals
- 21 Jun 2012 Additional company (Eli Lilly) added in association as reported by European Clinical Trials Database.
- 30 Aug 2011 Results were presented in a CoLucid Pharmaceuticals media release.
- 09 Jun 2010 Primary endpoint 'Headache severity' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History